| Otsuka Pharmaceutical Co., Ltd. | |
| Native Name: | 大塚製薬株式会社 |
| Native Name Lang: | ja |
| Romanized Name: | Ōtsuka Seiyaku Kabushiki-gaisha |
| Type: | Public KK |
| Traded As: | TOPIX 100 Component |
| Industry: | Pharmaceutical |
| Foundation: | (Founded) 1964 (Incorporated) |
| Founder: | Busaburo Otsuka |
| Location City: | Chiyoda, Tokyo |
| Location Country: | Japan |
| Locations: | 69 |
| Area Served: | Worldwide |
| Key People: | Tatsuo Higuchi (President) |
| Revenue: | ¥ 1.74 trillion |
| Revenue Year: | 2022 |
| Operating Income: | ¥ 150.32 billion |
| Income Year: | 2022 |
| Owner: | Nomura Trust and Banking investment trusts (11.43%) and investment trusts managed by other banks |
| Num Employees: | 5,634 |
| Num Employees Year: | 2017 |
| Parent: | Otsuka Holdings Co. Ltd |
| Homepage: | otsuka.com |
, abbreviated OPC, is a pharmaceutical company headquartered in Tokyo, Osaka and Naruto, Japan. The company was established August 10, 1964.
OPC's parent company Otsuka Holdings Co. Ltd. joined the Tokyo Stock Exchange through an initial public offering (IPO) on December 15, 2010, at which time Otsuka Holdings was Japan's No.2 drug maker by sales after industry leader Takeda Pharmaceutical Company. The IPO debuted at $2.4 billion, making it the largest for a pharmaceutical company up to that time.[1]
In 1955, the company started a football club called "Otsuka Pharmaceutical SC." In 2005 the name changed to Tokushima Vortis. The club is based in Naruto.[2]
In 2008, Otsuka Pharmaceutical Co. acquired 49% of Alma S.A., which is the parent company of CG Roxane.[3]
In early 2012, Otsuka announced it would focus its "future operations on CNS disorders and oncology". This decision necessitated a revision in the terms of an agreement with UCB to end collaboration on immunology products while continuing collaboration in the CNS area.
In March 2017, the company agreed to acquire Neurovance, Inc. for $250 million, gaining the firm's Phase III-ready ADHD drug centanafadine (previously EB-1020). Otsuka's subsidiary Otsuka America will pay $100 million upfront for Neurovance, plus up-to $150 million in development and approval milestones. As a result of the transaction, Neurovance will operate as an indirect, wholly owned subsidiary.[4]
In 2023, the company announced the acquisition of Mindset Pharma for $58.6 million.[5]